Cadrenal Therapeutics has partnered with Abbott for the TECH-LVAD trial to assess the safety and efficacy of tecarfarin in ...

In a breakthrough that researchers call an ‘unmitigated clinical success’, an artificial titanium-made heart has helped a man ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a ...

Doctors often treat these patients with a ventricular assist device, an implantable heart ... professor of internal medicine-cardiology at U-M Medical School. "If a malfunction or supply chain ...

Advocate Children's Hospital formally launched its pediatric heart transplant program at the Oak Lawn hospital today, having ...

This latest certification specifically acknowledges the hospital’s expertise in Transcatheter Aortic Valve Implantation (TAVI ...

Australia's first implant of a BiVACOR Total Artificial Heart has been announced as an unmitigated clinical success, with the patient becoming the ...

One person dies every 33 seconds from heart disease, making it the leading cause of death in the United States. But for one man who had the odds stacked against ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K ...